As 2016 approaches, it is an important time to look back on 2015 and all that the year entailed for stem cell advances. During 2016, I was honored to have interviewed a number of key thought leaders in the stem cell space, including the CEO of the largest dental stem cell company in the world (Tony Veverka of BioEden), Chief Business Officer for a company creating the world’s largest blood cell repository for iPSC production (James Lovgren of ORIG3N), and VP of Research and Development for one of the most innovative companies operating within the stem cell sector (Dr. Grynspan of Stem Cell Medicine).
Throughout 2015, my team and I conducted dozens of other interviews as well, with stem cell executives, investors, and researchers. These interviews were published on our stem cell industry blog and also informed market projections for BioInformant’s stem cell and cord blood market intelligence reports.
Below are the top five stem cell interviews of 2015, based on total number of page views, number of unique page views, and total number of social shares. Congratulations to the individuals below!
Top 5 Stem Cell Interviews of 2015
[#1 of 5] TOP STEM CELL INTERVIEW OF 2015: Jim Lovgren, Chief Business Officer of ORIG3N
[#2 of 5] 2ND STEM CELL INTERVIEW OF 2015: Dr. Frida Grynspan, VP of Research and Development for Stem Cell Medicine
Title: Exclusive Inside Story: Stem Cell Medicine to Develop Genetically Modified Muscle Progenitor Cells
[#3 of 5] 3RD STEM CELL INTERVIEW OF 2015: Tony Veverka, CEO of BioEden
Title: How Dental Stem Cells Will Impact Our Future – Q&A with BioEden Executive, Tony Veverka
[4th of 5] 4TH STEM CELL INTERVIEW OF 2015: Kyle Cetrulo, CEO of Auxocell
Title: Interview with Kyle Cetrulo, Perinatal Stem Cell Expert and CEO of AuxoCell Laboratories
[5th of 5] 5TH STEM CELL INTERVIEW OF 2015: Dr. Ornella Parolini, President of the International Placenta Stem Cell Society (IPLASS)
Title: Question & Answer with Placental Stem Cell Expert, Dr. Ornella Parolini
About Us
As the first and only market research firm to specialize in the stem cell industry, BioInformant’s research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, nd Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.